Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Cymabay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met The Primary Endpoint Of Reduction In Gout Flares - Yahoo Finance

CymaBay's gout drug meets main goal in mid-stage study - Yahoo Finance

Homebuilders are among the leaders with Barratt Developments and Persimmon up 2.5% and 1.0%, respectively. Energy names lag with Royal Dutch Shell and Petrofac both down near 0.5%. 8:36 am Seaspan announces extension of time charter terms by Yang Ming and expiry of Yang Ming's purchase option ( SSW ) : Co announced that Yang Ming Marine Transport has confirmed the term of the fixed-rate time charters for the five 14000 TEU SAVER design containerships currently being constructed image of gout at CSBC Corporation will be extended to ten years with one two-year option. Two of these vessels previously have been allocated to Seaspan and three have been allocated to Greater China Intermodal Investments under the right of first refusal agreement among Seaspan, GCI and Blue Water Commerce. 8:35 am Gold and silver initially fall modestly following retail sales data, dollar index inched modestly higher. Dec gold is now -0.2% at $1236.80/oz, Dec silver is -0.2% at $18.57/oz (:COMDX) : 8:35 am Rock Creek Pharma receives new dietary ingredient notification response; letter indicated that the FDA considers anatabine citrate a drug, because it provides anit-inflammatory support ( RCPI ) : Co announced it has received a written response from the FDA in response to the NDIN for the formulations of Anatabloc and CigRx submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed INDA.
For the original version including any supplementary diet gout images or video, visit http://finance.yahoo.com/news/inplay-briefing-com-175538006.html

CymaBay drug not better than current care in reducing uric acid - Yahoo News

This leads to the excretion of uric acid into the urine (a uricosuric effect).In addition, arhalofenate has an anti-inflammatory activity that is well suited to treating gout. Data from preclinical models show that it blocks the urate crystal-induced production of IL-1, explaining its ability to reduce gout flares. This dual mechanism of action differentiates arhalofenate from all currently available treatments for gout. Arhalofenate has established a favorable safety profile in clinical trials involving more than 1,000 patients exposed to date. About Hyperuricemia and Gout Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to urate crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Chronic recurrence of gout flares in joints leads to tissue destruction with loss of function and debilitation. According to the NHANES (2007-2008) study, over 45 million Americans have hyperuricemia and over 8 million have progressed to a diagnosis of gout.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-therapeutics-announces-positive-results-110000267.html

He attributed the lower-than-expected fall in uric acid levels to changes to data from patients not following the study design. The company said it was considering monotherapy and combination therapy for its late-stage study design. CymaBay said on Jan.12 that arhalofenate in combination with Takeda Pharmaceutical Co Ltd's febuxostat lowered serum uric acid levels, compared with placebo in an earlier mid-stage study. Gout is a condition affecting joints and muscles when the body acts against a build-up of uric acid in the blood. Described as a painful and common form of inflammatory arthritis, gout affects nearly 8.3 million Americans, according to the U.S. Centers for Disease Control and Prevention, citing data.
For the original version including any supplementary images or video, visit http://news.yahoo.com/cymabays-gout-drug-meets-main-goal-mid-stage-112622018--finance.html

InPlay from Briefing.com - Yahoo Finance

Here are the misconceptions, with debunkery below: 1. Peasants were a single class of people who were more or less equal to one another. It's easy to think that people in the Middle Ages were easily divided into very broad classes: royals, nobles, knights, clergy, and toiling peasants at the very bottom. But just because you didn't have "king," "lord," "sir," "father," or "brother" (or their female analogs) in front of your name doesn't mean you weren't concerned with your own social standing. There are vast classes of people whom, today, we might generally refer to as "peasants," but there were actually various classes of people within that broad category. Mortimer points out that, in 14th-century England, for example, you have your villeins, people bonded to a particular lord's land. Villeins were not considered free folk, and they could be sold with the lord's land.
For the original version including any supplementary images or video, visit http://io9.com/10-worst-misconceptions-about-medieval-life-youd-get-fr-1686799982

10 Worst Misconceptions About Medieval Life You'd Get From Fantasy Books

10 Worst Misconceptions About Medieval Life You "Results from our clinical program to date suggest that arhalofenate may represent a new paradigm for the treatment of gout," Pol Boudes, CymaBay's chief medical officer, said. This is the first study to show that arhalofenate produces reductions in flares without concomitant dosing of colchicine, the company said. Colchicine is an anti-inflammatory compound that is commonly prescribed to treat gout. The compound has been available in the United States for more than half a century in injectable form. Intravenous form of colchicine has been ordered off the market by the U.S. Food and Drug Administration because of toxicities and fatalities.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabays-gout-drug-meets-main-121904951.html

Don't be the product, buy the product!